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Von Willebrand factor (VWF) is a multifunctional adhesive protein that plays a key role in primary hemostasis. VWF circulates in the blood as an array of molecules ranging in size from small dimers [relative molecular mass (M r ) ϳ540 000] to high-molecular-mass (HMM) multimers (M r Ͻ20 000 000). Defects in the VWF molecule can lead to von Willebrand disease (VWD), a common bleeding disorder that affects 1% to 3% of the general population. VWD is highly heterogeneous and may be characterized by the absence or decrease of all forms of VWF, selective decrease of HMM forms of VWF, or loss of specific VWF function (1, 2 ) . The VWF classification system, updated by Sadler et al. (2 ) and accepted by the International Society on Thrombosis and Hemostasis, defines VWD according to the underlying defect as type 1, 2, or 3. VWD types 1 and 3 are characterized by the absence of or decrease in circulating VWF molecules and a proportional decrease in VWF activity (functional concordance). Type 2 VWD includes 4 major subtypes: 2A, 2B, 2M, and 2N, with various qualitative defects (1, 2 ) .
VWD diagnosis is based on clinical assessment and the results of VWF-specific laboratory tests. Differential diagnosis is crucial, because treatment varies with the subtype. Because no single test can detect all types of the disease, a combination of standard and VWF-specific coagulation assays is usually required, including factor VIII coagulant activity (FVIII:C), VWF antigen (VWF:Ag), ristocetin cofactor activity (VWF:RCo), VWF collagenbinding capacity (VWF:CB), and VWF multimer analysis (1) (2) (3) [see Fig. 1 in the Data Supplement that accompanies the online version of this Technical Brief at http:// www.clinchem.org/content/vol52/issue10]. The functional activity of VWF has traditionally been evaluated with the VWF:RCo assay, which measures the VWFmediated agglutination of platelets in the presence of ristocetin. The usefulness of this test, however, is limited by poor reproducibility and lack of calibration. VWF:CB activity depends on the presence and quantity of HMM VWF multimers. According to Favaloro et al. (3, 4 ) , VWD detection and differentiation between VWD types (particularly between types 1 and 2) depend mainly on the source of the collagen used in collagen binding assays (CBAs). Favaloro et al. reported the best results with collagen type I/III, but they also achieved good results with a commercial CBA ELISA produced by Gradipore (now Life Therapeutics). Recently, the Life Therapeutics CBA became commercially available in the U.S. This assay uses equine collagen Type III coated onto microtiter plates to bind HMM forms of VWF. Collagen-bound VWF molecules are detected with specific horseradish peroxidase-labeled anti-VWF conjugate. The resulting color intensity is proportional to the amount of plate-bound HMM multimers. A 5-point calibration curve (12.5%-200%) is used to quantify CBA activity. Results are reported as percent of the reference value for VWF:CB activity and as a VWF:CB/Ag ratio.
We evaluated the technical performance of this assay and its usefulness in conjunction with other assays (FVIII:C, VWF:Ag, VWF:RCo, and VWF multimer analysis) for laboratory diagnosis of VWD. We performed the CBA assay according to the manufacturer's instructions, with slight modifications. Extra dilutions [1/80 for "high" (results Ͼ200%) and either 1/20 or 1/10 for "low" (results Ͻ12.5%) samples] were added to extend the assay's reportable range. Reference intervals [mean (2 SD)] were established internally on the basis of results from 112 healthy volunteers (54 men, 58 women, age range 21-64 years). All volunteers provided written informed consent. (5, 6 ) . In 12 samples, we were not able to clearly differentiate between types 2A and 2B. However, because of a lack of clinical information and our inability to perform the ristocetin-induced platelet aggregation assay (caused by a lack of fresh platelets), we could not exclude VWD platelet type or acquired VWD. In this case, it was helpful to calculate the VWF:CBA/Ag ratio. Eighty-three percent of the VWD type 2A or 2B samples had VWF:CBA/Ag ratios of Ͻ0.5, indicating characteristic functional discordance. Our observations are in agreement with earlier reports (3, 4, 7 ) that the VWF:CB assay shows better reproducibility, and is more useful for differentiating type 2 VWD from type 1 than the VWF: RCo assay. Interestingly, 2 samples classified as type 2 by multimeric analysis had VWF:Ag, VWF:RCo, and VWF:CB values within reference intervals, even in the absence of HMM multimers (sample 1: woman, age 54 years, VWF:Ag 176%, VWF:RCo 44%, VWF:CB 97%; and sample 2: man, age not given, VWF:Ag 251%, VWF:RCo 55%, VWF:CB 90%). This pattern may be associated with an acquired VWD type such as essential thrombocythemia or aortic stenosis.
Antigenic and functional assays for 3 samples identified as type 3 VWD demonstrated virtual absence of VWF molecules (VWF:Ag Ͻ10%, CBA Ͻ3%, RCo Ͻ 20%, and absence of all multimers), suggesting that cold storage of the whole blood before plasma separation may have led to cold-induced loss of VWF functional activity (8 ) .
In 79 samples, we were unable to establish a definite identification of the VWD type. This subset was characterized by modest reductions in VWF:Ag values and no multimer abnormalities and could be classified as a type 1 VWD. However, the low VWF:Ag concentrations might have been associated with blood group O. Because the clinical history and blood group information were not available, these samples were classified as "possible VWD type 1".
Of the 2850 samples with no multimer pattern abnormalities, 135 (5%) had CBA values below the lower limit of the reference interval (Ͻ45%), but only 16 of these also had VWF:CB/Ag ratios Ͻ0.5, indicating functional discordance. These findings highlight the importance of interpreting VWF:CB activity in the context of all laboratory and clinical data, as is the case with the other VWF tests. We cannot exclude the possibility, however, that low VWF:CB results, in the absence of multimer pattern abnormalities, could point to isolated abnormalities in the VWF gene sequence at domain 1 and/or 3 containing collagen-binding sites (9 ) .
VWF:Ag concentrations and VWF functional activity are reportedly influenced by several variables, including ABO blood group (10, 11 ) . We evaluated the VWF:CB activity in a group of 88 healthy adults (43 men, 45 women, age range 18 -59 years) with known ABO blood group (Fig. 1) Because VWF:Ag concentrations showed similar blood group dependence, the VWF:CB/Ag ratio was not affected. These findings support earlier suggestions (2, 12 ) that the establishment of blood group-specific reference intervals could help in interpretation of VWF-specific assay results (2, 3, 11 ) . However, this issue is still under discussion (2, 11 ) . Overall, our findings indicate that this commercial CBA assay produces reliable results and will aid in the laboratory diagnosis of VWD. Results of a recent multilaboratory survey (12 ) indicate that laboratories not performing CBA testing have a 6-fold higher error rate for identification of VWD type 1 and are 10 times more likely to misclassify nonpathologic samples as VWD. As with the VWF:Ag and VWF:RCo assays, blood group-specific reference intervals may be useful for interpretation of VWF:CB results.
